JP2011503045A - Crth2拮抗化合物の使用 - Google Patents
Crth2拮抗化合物の使用 Download PDFInfo
- Publication number
- JP2011503045A JP2011503045A JP2010532660A JP2010532660A JP2011503045A JP 2011503045 A JP2011503045 A JP 2011503045A JP 2010532660 A JP2010532660 A JP 2010532660A JP 2010532660 A JP2010532660 A JP 2010532660A JP 2011503045 A JP2011503045 A JP 2011503045A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluoro
- acetic acid
- indol
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0722203.7A GB0722203D0 (en) | 2007-11-13 | 2007-11-13 | Use of CRTH2 antagonist compounds |
PCT/GB2008/003824 WO2009063202A2 (fr) | 2007-11-13 | 2008-11-13 | Utilisation de composés antagonistes de crth2 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2011503045A true JP2011503045A (ja) | 2011-01-27 |
Family
ID=38858584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010532660A Pending JP2011503045A (ja) | 2007-11-13 | 2008-11-13 | Crth2拮抗化合物の使用 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2219645A2 (fr) |
JP (1) | JP2011503045A (fr) |
DE (1) | DE08851028T1 (fr) |
ES (1) | ES2353055T1 (fr) |
GB (1) | GB0722203D0 (fr) |
WO (1) | WO2009063202A2 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011506415A (ja) * | 2007-12-14 | 2011-03-03 | プルマジェン セラピューティクス (アズマ) リミテッド | インドールおよびその治療的使用 |
JP2011509990A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
JP2011509988A (ja) * | 2008-01-18 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
WO2017104728A1 (fr) * | 2015-12-16 | 2017-06-22 | 国立大学法人東京大学 | Médicament destiné à traiter une allergie alimentaire |
JP2019521162A (ja) * | 2016-07-21 | 2019-07-25 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crth2阻害剤としてのインドール誘導体 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
NZ587709A (en) | 2008-02-01 | 2012-06-29 | Panmira Pharmaceuticals Llc | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
JP2011526281A (ja) | 2008-06-24 | 2011-10-06 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体のシクロアルカン[b]インドールアンタゴニスト |
EP2307362A4 (fr) | 2008-07-03 | 2012-05-09 | Panmira Pharmaceuticals Llc | Antagonistes des recepteurs de la prostaglandine d2 |
GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
WO2010057118A2 (fr) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Antagonistes hétérocycliques des récepteurs de la prostaglandine d2 |
EP2461809A4 (fr) | 2009-07-31 | 2013-06-19 | Panmira Pharmaceuticals Llc | Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2 |
SG178252A1 (en) | 2009-08-05 | 2012-03-29 | Panmira Pharmaceuticals Llc | Dp2 antagonist and uses thereof |
SG182398A1 (en) | 2010-01-06 | 2012-08-30 | Panmira Pharmaceuticals Llc | Dp2 antagonist and uses thereof |
RU2562255C2 (ru) | 2010-03-22 | 2015-09-10 | Актелион Фармасьютиклз Лтд | Производные 3-(гетероариламино)-1,2,3,4-тетрагидро-9н-карбазола и их применение в качестве модуляторов рецепторов простагландина d2 |
ES2635030T3 (es) * | 2010-12-23 | 2017-10-02 | Merck Sharp & Dohme Corp. | Quinoxalinas y aza-quinoxalinas como moduladores del receptor CRTH2 |
GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
KR101928595B1 (ko) | 2011-04-14 | 2018-12-12 | 이도르시아 파마슈티컬스 리미티드 | 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도[1,2-a]인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절자로서의 이의 용도 |
CN103086943B (zh) * | 2011-11-04 | 2015-04-15 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的吲哚类衍生物 |
HUE039614T2 (hu) | 2014-03-17 | 2019-01-28 | Idorsia Pharmaceuticals Ltd | Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk |
CA2938107A1 (fr) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Derives d'acide aza-indol-acetique et leur utilisation comme modulateurs des recepteurs de la prostaglandine d2 |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
UA123156C2 (uk) | 2015-09-15 | 2021-02-24 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007509114A (ja) * | 2003-10-23 | 2007-04-12 | オキサジェン リミテッド | 治療におけるcrth2アンタゴニストの使用 |
JP2010500966A (ja) * | 2006-07-22 | 2010-01-14 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0504150D0 (en) * | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
GB0605743D0 (en) * | 2006-03-22 | 2006-05-03 | Oxagen Ltd | Salts with CRTH2 antagonist activity |
-
2007
- 2007-11-13 GB GBGB0722203.7A patent/GB0722203D0/en not_active Ceased
-
2008
- 2008-11-13 ES ES08851028T patent/ES2353055T1/es active Pending
- 2008-11-13 DE DE08851028T patent/DE08851028T1/de active Pending
- 2008-11-13 WO PCT/GB2008/003824 patent/WO2009063202A2/fr active Application Filing
- 2008-11-13 JP JP2010532660A patent/JP2011503045A/ja active Pending
- 2008-11-13 EP EP08851028A patent/EP2219645A2/fr not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007509114A (ja) * | 2003-10-23 | 2007-04-12 | オキサジェン リミテッド | 治療におけるcrth2アンタゴニストの使用 |
JP2010500966A (ja) * | 2006-07-22 | 2010-01-14 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
Non-Patent Citations (1)
Title |
---|
JPN7014000537; 'The Effects of OC000459 on Nasal Mediators' ClinicalTrials.gov Archive , 20060210 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011506415A (ja) * | 2007-12-14 | 2011-03-03 | プルマジェン セラピューティクス (アズマ) リミテッド | インドールおよびその治療的使用 |
JP2011509988A (ja) * | 2008-01-18 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
JP2014159465A (ja) * | 2008-01-18 | 2014-09-04 | Oxagen Ltd | Crth2アンタゴニスト活性を有する化合物 |
JP2011509990A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
WO2017104728A1 (fr) * | 2015-12-16 | 2017-06-22 | 国立大学法人東京大学 | Médicament destiné à traiter une allergie alimentaire |
JP2019521162A (ja) * | 2016-07-21 | 2019-07-25 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crth2阻害剤としてのインドール誘導体 |
JP7044754B2 (ja) | 2016-07-21 | 2022-03-30 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Crth2阻害剤としてのインドール誘導体 |
Also Published As
Publication number | Publication date |
---|---|
GB0722203D0 (en) | 2007-12-19 |
WO2009063202A3 (fr) | 2009-08-27 |
DE08851028T1 (de) | 2011-02-24 |
ES2353055T1 (es) | 2011-02-25 |
WO2009063202A2 (fr) | 2009-05-22 |
EP2219645A2 (fr) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011503045A (ja) | Crth2拮抗化合物の使用 | |
WO2009063215A2 (fr) | Utilisation de composés antagonistes de crth2 | |
US20110124683A1 (en) | Use of CRTH2 Antagonist Compounds | |
US20130052190A1 (en) | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions | |
ES2442717T3 (es) | Compuestos que tienen actividad antagonista de CRTH2 | |
JP4313819B2 (ja) | 治療におけるcrth2アンタゴニストの使用 | |
JP5529362B2 (ja) | 鼻炎/結膜炎の治療のために、ロイコトリエンの作用に影響する物質による非鎮静抗ヒスタミン薬の新規な組み合わせ | |
JP2017081959A (ja) | 免疫関連疾患及び炎症性疾患の治療における3−(5−アミノ−2−メチル−4−オキソキナゾリン−3(4h)−イル)ピペリジン−2,6−ジオンの使用 | |
JP2007533725A (ja) | Crth2受容体アンタゴニストを用いたニューロパシー性疼痛処置方法 | |
PT1505973E (pt) | Combinações para o tratamento de mieloma múltiplo | |
SK13952002A3 (sk) | Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén | |
JP2020513005A (ja) | Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物 | |
JP2011184460A (ja) | 5−ht1a受容体サブタイプ作動薬 | |
JP6621534B2 (ja) | 慢性咳の処置のためのオルブピタント | |
JP6961622B2 (ja) | 併存疾患としてアパシーを伴うアルツハイマー病の治療における使用のための5−ht6受容体アンタゴニスト | |
KR20060130619A (ko) | 유기 화합물의 조합물 | |
JPH06506192A (ja) | 阻害剤 | |
WO2017041112A1 (fr) | Combinaisons de kétamine et d'inhibiteur du cytochrome p 450 | |
KR20200067859A (ko) | Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물 | |
JPWO2004032964A1 (ja) | アレルギー性疾患治療剤 | |
WO2016006621A1 (fr) | Médicament contenant un antagoniste de pgd2 pour le traitement des symptômes associés aux maladies allergiques | |
JP2019524682A (ja) | 抗うつ作用の速い発現のためのボルチオキセチン投与計画 | |
JP2013542262A (ja) | デキサメタゾン併用療法 | |
JP5195418B2 (ja) | 機能性脳疾患治療剤 | |
JP4677705B2 (ja) | 頭痛の予防および/または治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130507 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140218 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140516 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140708 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141118 |